Merck Licenses SPR2015 from SciBrunch for $2.13 Billion

Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor.

The deal complements Merck's expanding pipeline of precision-targeted candidates and provides access to a potent engineered inhibitor targeting one of the most prevalent mutant forms of KRAS found in human cancers.

Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture, and commercialize SPR2015 worldwide. The company will receive an upfront payment of $400 million and is eligible for milestone payments related to development, commercialization, and other activities across multiple indications.

The total potential aggregate value of the transaction, including the upfront payment, is $2.13 billion.